Clinical Trials | April 22, 2026
Novo Nordisk’s Etavopivat delivers major Phase 3 win in sickle cell disease
By cutting pain crises & boosting haemoglobin
By cutting pain crises & boosting haemoglobin
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Subscribe To Our Newsletter & Stay Updated
